VERU
HEALTHCAREVeru Inc
$2.22+0.01 (+0.45%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VERU Today?
No stock-specific AI insight has been generated for VERU yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.06$7.40
$2.22
Fundamentals
Market Cap$36M
P/E Ratio—
EPS$-1.21
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume73K
Avg Volume (10D)—
Shares Outstanding16.1M
VERU News
21 articles- Veru Inc. (VERU.US) is scheduled to release its earnings report before the market opens on May 13.富途牛牛·May 7, 2026
- Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13thYahoo Finance·May 6, 2026
- Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight LossYahoo Finance·Mar 9, 2026
- Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 19, 2026
- Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesYahoo Finance·Feb 11, 2026
- Veru Inc. Q1 2026 Earnings Call SummaryMoby·Feb 11, 2026
- Veru (VERU) Q1 2026 Earnings Call TranscriptMotley Fool·Feb 11, 2026
- Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program ProgressYahoo Finance·Feb 11, 2026
- Veru to Report Fiscal 2026 First Quarter Financial Results on February 11thYahoo Finance·Feb 4, 2026
- Veru Inc (VERU) Q4 2025 Earnings Call Highlights: Strategic Shifts and Financial ChallengesYahoo Finance·Dec 17, 2025
- Veru Reports Fiscal Year 2025 Financial Results and Clinical Program ProgressYahoo Finance·Dec 17, 2025
- Veru to Report Fiscal Year 2025 Financial Results on December 17thYahoo Finance·Dec 10, 2025
- Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory WorkshopYahoo Finance·Dec 4, 2025
- Veru to Present Two Abstracts at ObesityWeek 2025Yahoo Finance·Oct 31, 2025
- Veru Announces Pricing of $25 Million Public OfferingYahoo Finance·Oct 30, 2025
- Veru Announces Proposed Public OfferingYahoo Finance·Oct 29, 2025
- October 2025's Noteworthy Penny StocksYahoo Finance·Oct 8, 2025
- Onconetix announces financing through private placement, debt settlementYahoo Finance·Sep 27, 2025
- Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.Yahoo Finance·Sep 26, 2025
- Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of ObesityYahoo Finance·Sep 23, 2025
- Veru Announces Novel Modified-Release Oral Formulation for EnobosarmYahoo Finance·Aug 15, 2025
All 21 articles loaded
Price Data
Open$2.28
Previous Close$2.21
Day High$2.35
Day Low$2.21
52 Week High$7.40
52 Week Low$2.06
52-Week Range
$2.06$7.40
$2.22
Fundamentals
Market Cap$36M
P/E Ratio—
EPS$-1.21
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume73K
Avg Volume (10D)—
Shares Outstanding16.1M
About Veru Inc
Veru Inc., an oncology biopharmaceutical company, focuses on the development of drugs for the treatment of cancers. The company is headquartered in Miami, Florida.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—